DHEA and DHEA-S levels in hospitalized adolescents with first-episode schizophrenia and conduct disorder: A comparison study

European Neuropsychopharmacology

Volumn 19, Issue 7, 2009, Pages 499-503

  Strous, Rael D ^a,b   Maayan, Rachel ^b   Kaminsky, Masha ^a   Blumensohn, Rachel ^a,b   Weizman, Abraham ^b,c   Spivak, Baruch ^a,b  

^a NESS ZIONA MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

DHEA S; ; DHEA; ; First episode psychosis; Schizophrenia;

Indexed keywords

HYDROCORTISONE; NEUROSTEROID; PRASTERONE; PRASTERONE SULFATE;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONDUCT DISORDER; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA;

ADOLESCENT; CONDUCT DISORDER; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; HOSPITALIZATION; HUMANS; HYDROCORTISONE; MALE; PSYCHIATRIC STATUS RATING SCALES; RADIOIMMUNOASSAY; SCHIZOPHRENIA; TIME FACTORS; YOUNG ADULT;

EID: 67349224661     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.03.001     Document Type: Article

References (36)

1. Baulieu E.E., and Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. J. Endocrinol. 150 (1996) S221-S239
2. Brophy M.H., Rush A.J., and Crowley G. Cortisol, estradiol, and androgens in acutely ill paranoid schizophrenics. Biol. Psychiatry 18 (1983) 583-590
3. Cardounel A., Regelson W., and Kalimi M. Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. Proc. Soc. Exp. Biol. Med. 222 (1999) 145-149
4. Corpechot C., Robel P., Axelson M., Sjovall J., and Baulieu E.E. Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. Proc Natl Acad Sci USA 78 (1981) 4704-4707
5. di Michele F., Caltagirone C., Bonaviri G., Romeo E., and Spalletta G. Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia. J. Psychiatr. Res. 39 (2005) 267-273
6. Friess E., Schiffelholz T., Steckler T., and Steiger A. Dehydroepiandrosterone-a neurosteroid. Eur. J. Clin. Invest. 30 Suppl 3 (2000) 46-50
7. Golubchik P., Mozes T., Maayan R., and Weizman A. Neurosteroid blood levels in delinquent adolescent boys with conduct disorder. Eur. Neuropsychopharmacol. 19 (2009) 49-52
8. Goodyer I.M., Park R.J., Netherton C.M., and Herbert J. Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology. Br. J. Psychiatry 179 (2001) 243-249
9. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
10. Harris D.S., Wolkowitz O.M., and Reus V.I. Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. World J. Biol. Psychiatry 2 (2001) 99-102
11. Hu Y., Cardounel A., Gursoy E., Anderson P., and Kalimi M. Anti-stress effects of dehydroepiandrosterone: protection of rats against repeated immobilization stress-induced weight loss, glucocorticoid receptor production, and lipid peroxidation. Biochem. Pharmacol. 59 (2000) 753-762
12. Kay S., Fiszbein A., and Opler L.A. The positive and negative syndrome scale for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
13. Kaufman J., Birmaher B., and Brent D. Kiddie-SADS- Present and Lifetime Version. Version 1.0 of October 1996 ed. (1996), The Dept. of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh
14. Kroboth P.D., Salek F.S., Pittenger A.L., Fabian T.J., and Frye R.F. DHEA and DHEA-S: a review. J. Clin. Pharmacol. 39 (1999) 327-348
15. Maayan R., Yagorowski Y., Grupper D., Weiss M., Shtaif B., Kaoud M.A., and Weizman A. Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients. Biol. Psychiatry 48 (2000) 693-701
16. Majewska M.D. Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog. Neurobiol. 38 (1992) 379-395
17. Monteleone P., Luisi M., Colurcio B., Casarosa E., Monteleone P., Ioime R., Genazzani A.R., and Maj M. Plasma levels of neuroactive steroids are increased in untreated women with anorexia nervosa or bulimia nervosa. Psychosom. Med. 63 (2001) 62-68
18. Oades R.D., and Schepker R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology 19 (1994) 373-385
19. Oberbeck R., Benschop R.J., Jacobs R., Hosch W., Jetschmann J.U., Schurmeyer T.H., Schmidt R.E., and Schedlowski M. Endocrine mechanisms of stress-induced DHEA-secretion. J. Endocrinol. Invest. 21 (1998) 148-153
20. Paul S.M., and Purdy R.H. Neuroactive steroids. FASEB J. 6 (1992) 2311-2322
21. Pisu M.G., and Serra M. Neurosteroids and neuroactive drugs in mental disorders. Life Sci. 74 (2004) 3181-3197
22. Plutchik R., and van Praag H.M. The measurement of suicidality, aggressivity and impulsivity. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 13 (1989) 23-34
23. Rapoport J.L., Addington A.M., Frangou S., and Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry 10 (2005) 434-449
24. Ritsner M., Maayan R., Gibel A., Strous R.D., Modai I., and Weizman A. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur. Neuropsychopharmacol. 14 (2004) 267-273
25. Ritsner M., Gibel A., Maayan R., Ratner Y., Ram E., Biadsy H., Modai I., and Weizman A. Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Neuropsychopharmacology 30 (2005) 1913-1922
26. Ritsner M., Gibel A., Ram E., Maayan R., and Weizman A. Alterations in DHEA metabolism in schizophrenia: two-month case-control study. Eur. Neuropsychopharmacol. 16 (2006) 137-146
27. Rupprecht R., di Michele F., Hermann B., Strohle A., Lancel M., Romeo E., and Holsboer F. Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacology. Brain Res. Rev. 37 (2001) 59-67
28. Schumacher M., Weill-Engerer S., Liere P., Robert F., Franklin R.J., Garcia-Segura L.M., Lambert J.J., Mayo W., Melcangi R.C., Parducz A., Suter U., Carelli C., Baulieu E.E., and Akwa Y. Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog. Neurobiol. 71 (2003) 3-29
29. Sondergaard H.P., Hansson L.O., and Theorell T. Elevated blood levels of dehydroepiandrosterone sulphate vary with symptom load in posttraumatic stress disorder: findings from a longitudinal study of refugees in Sweden. Psychother. Psychosom. 71 (2002) 298-303
30. Spivak B., Maayan R., Kotler M., Mester R., Gil-Ad I., Shtaif B., and Weizman A. Elevated circulatory level of GABA(A)-antagonistic neurosteroids in patients with combat-related post-traumatic stress disorder. Psychol. Med. 30 (2000) 1227-1231
31. Strous R.D., Spivak B., Yoran-Hegesh R., Maayan R., Averbuch E., Kotler M., Mester R., and Weizman A. Analysis of neurosteroid levels in attention deficit hyperactivity disorder. Int. J. Neuropsychopharmacol. 4 (2001) 259-264
32. Strous R.D., Maayan R., Lapidus R., Stryjer R., Lustig M., Kotler M., and Weizman A. Value of dehydroepiandrosterone (DHEA) augmentation in the management of negative symptoms in schizophrenia. Arch. Gen. Psychiatry 60 (2003) 133-141
33. Strous R.D., Maayan R., Lapidus R., Goredetsky L., Zeldich E., Kotler M., and Weizman A. Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophr. Res. 71 (2004) 427-434
34. Tourney G., and Hatfield L. Plasma androgens in male schizophrenics. Arch. Gen. Psychiatry 27 (1972) 753-755
35. van Broekhoven F., and Verkes R.J. Neurosteroids in depression: a review. Psychopharmacology 165 (2003) 97-110
36. Yudofsky S.C., Silver J.M., Jackson W., Endicott J., and Williams D. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am. J. Psychiatry 143 (1986) 35-39